Form 4: Aclaris Therapeutics Executive Granted Stock Options and Restricted Stock Units

Aclaris Therapeutics' President and COO, Hugh M. Davis, received stock options and restricted stock units as part of an inducement plan.

Summary

• Hugh M. Davis, President and COO of Aclaris Therapeutics, was granted 375,000 stock options and 107,000 restricted stock units on December 2, 2024.
• The stock options have an exercise price of $3.96 and vest over four years, with 25% vesting on each anniversary of the grant date.
• The restricted stock units also vest over four years, with 25% vesting on each anniversary of the grant date.
• Both the stock options and restricted stock units were granted as a material inducement for Mr. Davis's employment with Aclaris Therapeutics.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

The granting of stock options and restricted stock units is a common practice in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are standard practice for executive compensation in the biotech industry.
• Vesting schedules of four years with annual vesting are typical for these types of grants.
• Companies like Regeneron, Vertex, and Biogen also use similar equity-based compensation plans to incentivize their executives.

Stakeholder Impact

• Shareholders may view the grants positively as they incentivize management to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, executive compensation, inducement plan, vesting, Aclaris Therapeutics, ACRS, Hugh M. Davis